NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 6 - Endocrine system 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing

06.01.02.03 Other antidiabetic drugs
06.01.02.03 DPP-4 inhibitors

Sitagliptin tablets (Januvia®)

First Choice

Entry reviewed: May 2022

Alogliptin tablets

Second Choice

If sitagliptin is not tolerated and a gliptin is indicated as per NICE NG 28 guideline

Takeda have discontinued the Vipidia brand, must be prescribed as generic. 

Entry reviewed: September 2024

Linagliptin tablets (Trajenta®)

Second Choice

For patients with history of reduced renal function(eGFR <45ml/min) where reduced dose of sitagliptin is not suitable

Entry reviewed: May 2022

06.01.02.03 GLP-1 mimetics
06.01.02.03 SGLT2 inhibitors
06.01.02.03 Other
Classifications
May be initiated in any care setting
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.